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Condensation: Female cancer survivors have increased risks of premature delivery and low 90 
birth weight associated with radiotherapy exposing the uterus, which warrant high-risk 91 
pregnancy surveillance. 92 
Running head: IGHG recommendations for management of obstetric risks for female CAYA 93 
survivors 94 
 95 
AJOG at a glance: 96 
Why was this study conducted? National guidelines that identify specific adverse pregnancy 97 
outcomes and the clinical characteristics of childhood, adolescent, and young adult (CAYA) 98 
cancer survivors are scarce and vary in content. 99 
What are the key findings? There are increased risks of premature delivery and low birth 100 
weight associated with radiotherapy exposing the uterus and pregnancy-related 101 
cardiomyopathy following treatment with anthracyclines.   102 
What does this study add to what is already known? This guideline from the International 103 
Late Effects of Childhood Cancer Guideline Harmonization Group identifies specific adverse 104 
obstetric related outcomes that are increased in CAYA cancer survivors, to characterize the 105 
population that will benefit specifically from an individualized preconception consultation 106 
and pregnancy surveillance. 107 
Keywords: prenatal care; late effects; childhood cancer survivors;  fecundity; pregnancy;  108 
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ABSTRACT  109 
Objective: Female childhood, adolescent, and young adult (CAYA) cancer survivors have an 110 
increased risk of adverse pregnancy outcomes related to their cancer or treatment-111 
associated sequelae. Optimal care for CAYA cancer survivors can be facilitated by clinical 112 
practice guidelines that identify specific adverse pregnancy outcomes and the clinical 113 
characteristics of at-risk subgroups. However, national guidelines are scarce and vary in 114 
content. Here, the International Late Effects of Childhood Cancer Guideline Harmonization 115 
Group (IGHG) offers recommendations for the counselling and surveillance of obstetric risks 116 
of CAYA survivors.   117 
Data sources: A systematic literature search in MEDLINE (through PubMed) to identify all 118 
available evidence published between January 1990 and December 2018.  119 
Study eligibility criteria: Published articles on pregnancy, perinatal or congenital risks in 120 
female cancer survivors were screened for eligibility. Study designs with a sample size larger 121 
than 40 pregnancies in CAYA cancer survivors (diagnosed before age 25, not pregnant at that 122 
time) were eligible.  123 
Study appraisal and synthesis methods: This guideline from the IGHG systematically 124 
appraised the quality of available evidence for adverse obstetric outcomes in CAYA cancer 125 
survivors using GRADE methodology, and formulated recommendations to enhance 126 
evidence-based obstetric care and preconception counseling of female CAYA cancer 127 
survivors.  128 
Results: Healthcare providers should discuss the risk of adverse obstetric outcomes based on 129 
cancer treatment exposures with all female CAYA cancer survivors of reproductive age, 130 
before conception. Health care providers should be aware that there is no evidence to 131 
support an increased risk of giving birth to a child with congenital anomalies (high quality 132 
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evidence). Survivors treated with radiotherapy to volumes exposing the uterus and their 133 
health care providers should be aware of the risk of adverse obstetric outcomes including 134 
miscarriage (moderate quality evidence), premature birth (high quality evidence) and low 135 
birth weight (high quality evidence); therefore, high risk obstetric surveillance is 136 
recommended. Cardiomyopathy surveillance is reasonable prior to pregnancy or in the first 137 
trimester for all female survivors treated with anthracyclines and/or chest radiation.  138 
Conclusions: Female cancer survivors have increased risks of premature delivery and low 139 
birth weight associated with radiotherapy targeting the lower body and thereby exposing 140 
the uterus, which warrant high-risk pregnancy surveillance. 141 
142 
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INTRODUCTION 143 
Five year survival rates for childhood, adolescent, and young adult (CAYA) cancer patients 144 
now approach 80%1. Consequently, increasing numbers of CAYA cancer survivors are at risk 145 
for adverse physical and psychosocial complications from their cancer and/or its treatment2. 146 
Reproductive health, and specifically pregnancy and delivery outcomes, represent a critical 147 
area for long-term follow-up as having children is an important determinant of quality of life 148 
for CAYA cancer survivors3-7. 149 
Previous research indicates difficulty conceiving or carrying a pregnancy to term, as well as 150 
excess risk of adverse pregnancy outcomes, among CAYA cancer survivors . For example, the 151 
risks of premature birth and postpartum hemorrhage are higher in CAYA cancer survivors 152 
compared to women who did not have cancer8-13, and these risks are further increased in 153 
survivors treated with abdominopelvic radiotherapy9, 11-14. Evidence-based clinical guidelines 154 
on surveillance in pregnancy can identify the type and prevalence of specific obstetric and 155 
perinatal complications, characterize the clinical features of those at risk, help survivors 156 
make informed decisions, facilitate counseling and timely referral to high-risk obstetric care, 157 
and enable opportunities for interventions to optimize pregnancy outcomes. 158 
 159 
OBJECTIVE 160 
Published clinical practice guidelines by North American and European cancer groups 161 
reference general obstetric risks 15-18, but do not comprehensively assess the clinical features 162 
of those who could benefit from high-risk obstetric follow-up. Herein, we summarize the 163 
results of a systematic review undertaken by the International Late Effects of Childhood 164 
Cancer Guideline Harmonization Group (IGHG) and present a critical appraisal of available 165 
evidence on obstetric risks in CAYA cancer survivors, synthesizing these findings into 166 
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evidence-based recommendations for surveillance and counseling of CAYA cancer survivors 167 
during pregnancy and delivery due to their cancer or cancer treatment.  168 
 169 
METHODS 170 
This guideline focuses on facilitating timely identification of CAYA cancer survivors at high-171 
risk of obstetric complications diagnosed with cancer before age 25 years (and not pregnant 172 
at that time) who would benefit from preconception counseling and surveillance during 173 
pregnancy. Management of obstetric complications is beyond the scope of the present 174 
guideline, which should defer to standards established by local/national health systems. 175 
Standardized definitions used in this guideline are presented in Appendix 1.  176 
The obstetric guideline panel consisted of 33 experts from the United States of America, 177 
United Kingdom, Denmark, Germany, France, New Zealand, Australia, Japan and the 178 
Netherlands from relevant disciplines, including gynecology, obstetrics, midwifery, 179 
endocrinology, pediatric oncology, radiation oncology, epidemiology, and guideline 180 
methodology, as well as CAYA survivor/family representatives. 181 
Methods of the IGHG have been described previously19. For this guideline, concordances and 182 
discordances across existing survivorship guidelines of the North American Children’s 183 
Oncology Group (COG)15, the Dutch Childhood Oncology Group (DCOG)16, the Scottish 184 
Intercollegiate Guidelines Network (SIGN)18, and the UK Children’s Cancer and Leukaemia 185 
Group (UKCCLG)17 were evaluated. We defined the major outcomes for obstetric problems 186 
in survivors and congenital problems in offspring (Appendix 1). For all discordances and 187 
relevant outcomes, focused clinical questions were formulated to determine whether 188 
specific preconception consultation or surveillance was indicated. Four working groups 189 
evaluated the following topics: 1) adverse fetal outcomes in pregnancy (such as miscarriage); 190 
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2) adverse maternal outcomes in pregnancy; 3) delivery outcomes; and 4) congenital 191 
anomalies of the neonate.  192 
A systematic literature search was performed in MEDLINE (through PubMed) to identify all 193 
available evidence published between January 1990 and December 2018, using the search 194 
terms “childhood cancer”, “survivors”, “late effects” and “obstetric problems”. Details of the 195 
full search strategy are included in Appendix 2. All study designs with a sample size larger 196 
than 40 pregnancies in female childhood cancer survivors were eligible. To ensure rigorous 197 
review of manuscripts by at least two individuals, only studies published in English were 198 
selected for analysis. All abstracts were screened by two independent reviewers (ALLFK and 199 
one working group member). Disagreements were resolved through consensus. Cross-200 
reference checking was performed to identify additional studies overlooked during the initial 201 
search. Relevant articles were summarized in one evidence table by two reviewers (ALLFK 202 
and one working group member), including a critical appraisal of risks of bias (Appendix 3). 203 
The evidence tables were subsequently assembled into summary of findings tables (ALFFK) 204 
and revised where necessary (RLM, LCMK). We assessed the quality of the body of evidence 205 
for each clinical question according to criteria based on Grading of Recommendations 206 
Assessment Development and Evaluation (GRADE)20 (Appendix 4). The quality of the total 207 
body of evidence is graded according to four levels: High (⊕⊕⊕⊕), further research is 208 
unlikely to change the confidence in the estimate of effect; Moderate (⊕⊕⊕⊖), further 209 
research is likely to have an important impact on the confidence in the estimate of effect 210 
and may change the estimate; Low (⊕⊕⊖⊖), further research is very likely to have an 211 
important impact on the confidence in the estimate of effect and is likely to change the 212 
estimate; and Very low (⊕⊖⊖⊖), any estimate of effect is very uncertain. The level of 213 
evidence decreased in the presence of study limitations (risk of bias in the studies), 214 
9 
 
inconsistency of results between studies, indirectness of the study populations or outcomes, 215 
or imprecision of the effect estimates. The level of evidence increased if the effect sizes 216 
were large or there was evidence for a dose-response relationship. 217 
 218 
Translating evidence into recommendations 219 
Recommendations were drafted considering the level of the evidence, other effects of the 220 
expected risks (such as unnecessary medicalization), and the need for flexibility across 221 
health care systems 21. Terminology employed for radiotherapy and obstetric outcomes can 222 
be found in Appendix 5. Decisions were made through iterative group discussions, final 223 
recommendations represent unanimous consensus. The strength of the recommendations 224 
was graded according to published evidence-based methods (Appendix 4). 225 
Recommendations were classified into strong or moderate recommendations, and based on 226 
high quality evidence, moderate quality evidence or expert opinion19, 21, 22. Pregnancy care-227 
related recommendations from the IGHG cardiomyopathy guideline were adopted in this 228 
guideline to provide a complete overview of recommendations for pregnancy surveillance. 229 
The final harmonized recommendations were critically appraised by four independent 230 
external experts in the field and two survivor representatives.  231 
 232 
RESULTS 233 
Discordances across existing LTFU guidelines 234 
Identification of concordances and discordances amongst existing surveillance 235 
recommendations is displayed in Appendix 6. The literature search yielded 2,772 abstracts 236 
for pregnancy and delivery related risks and 2,492 abstracts for congenital anomalies. In 237 
total, 98 full texts were reviewed, and 28 articles were included (Figure 1, included articles 238 
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in Appendix 7). The evidence tables and summary of findings are presented in Appendix 8. 239 
The conclusions of evidence tables including GRADE assessment are summarized in Table 1 240 
and Appendix 9 and depicted in a color scheme in Appendix 10.  241 
 242 
Who needs preconception consultation or specific obstetric surveillance? 243 
Evidence for risks during pregnancy 244 
Miscarriage 245 
There is moderate level evidence that CAYA cancer survivors treated with radiotherapy to 246 
volumes exposing the uterus are at increased risk of miscarriage compared to the general 247 
population9, 14, 23-29. However, this association was only borderline significant in a large cohort 248 
from the British Childhood Cancer Survivor Study (BCCSS)26 and not significant in two smaller 249 
studies24, 28. There is only low level evidence for a dose-response relationship29, 30. The 250 
evidence indicated no significant effect due to chemotherapy9, 26, 30, 31.  251 
 252 
Termination of pregnancy  253 
There is no data indicating an increased risk of medically-induced terminations (very low 254 
level evidence)14, 23, 26, 29, 32  among CAYA cancer survivors in general. However, there is (very) 255 
low level evidence for an increased risk for termination of pregnancy after any 256 
radiotherapy14, 26 and chemotherapy14, 26. Of note, these findings are compromised by 257 
terminology in the relevant reports that limits the distinction between medically-indicated 258 
and elective termination of pregnancy. 259 
 260 
Stillbirth 261 
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There is no data indicating an increased risk of stillbirth (moderate level evidence) in CAYA 262 
cancer survivors in general9, 29, and low level evidence for increased risk of stillbirth after 263 
moderate to high doses of ovarian-uterine radiotherapy (>10 Gy)33 or abdominopelvic 264 
radiotherapy (>25 Gy)30.  265 
 266 
Gestational hypertension 267 
There is very low level evidence for an effect of radiotherapy on the risk of gestational 268 
hypertension in CAYA cancer survivors as compared to survivors treated without 269 
radiotherapy. The increased risk was only reported in the abdominopelvic irradiated 270 
survivors who had been diagnosed with Wilms tumor in the BCCSS34, while two smaller 271 
studies did not find this association13, 35. A paper from the National Wilms Tumor Study 272 
Group observed an increased risk of any hypertensive disorder of pregnancy with increasing 273 
doses of flank radiotherapy, but as this was the only identified study assessing radiotherapy 274 
dose, the level of evidence is very low.  275 
 276 
Pre-eclampsia 277 
There is low level evidence for an increased risk of pre-eclampsia in CAYA cancer survivors as 278 
compared to controls, as this association was reported in one large population-based 279 
Australian study9 but not in two other studies11, 13. Of note, one of these studies concerned a 280 
small sub-cohort of 6 CAYA cancer survivors exposed to radiotherapy to the abdomen, none 281 
of whom developed pre-eclampsia13. No studies were identified that evaluated the risk of 282 
pre-eclampsia after chemotherapy.  283 
 284 
Maternal anemia 285 
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There is low level evidence that abdominopelvic radiotherapy increases the risk of maternal 286 
anemia in CAYA cancer survivors as compared to non-irradiated survivors. This is based on 287 
increased risks observed in one large study34 while the effect was not observed in another 288 
equally-sized cohort11.  289 
 290 
Gestational diabetes 291 
There is low level evidence overall for an increased risk of gestational diabetes in CAYA 292 
cancer survivors as compared to controls, based on one report that found the association9 293 
and two that did not show an association11, 35. There is low level evidence for an effect of 294 
abdominopelvic radiotherapy9, 11, 34, 35, moderate level evidence that there is no effect of 295 
chemotherapy, 9, 11, 35 and high level evidence that there is no effect of age at diagnosis9, 11, 34 296 
on the risk of gestational diabetes. 297 
 298 
Malposition of the fetus 299 
There is no increased risk of malposition of the fetus (low level evidence), and no effect of 300 
radiotherapy on this outcome (very low level evidence)10, 34.  301 
 302 
Evidence for gestational length and birth weight 303 
Premature birth 304 
CAYA cancer survivors are at increased risk of premature birth (before 37 weeks of 305 
gestation) as compared to siblings and the general population (moderate level evidence)9-13, 306 
27, 28, 35. High level evidence showed that radiotherapy to volumes exposing the uterus 307 
increases the risk of premature birth9, 11, 13, 28, 34, 35. Two reports did not delineate specific 308 
radiotherapy volumes, categorizing groups only as treated with or without any type of 309 
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radiotherapy; but both also showed increased risk after treatment with radiotherapy9, 11. We 310 
found low level evidence for a dose response relationship with radiotherapy, including one 311 
study that showed a trend for increasing risk with increasing flank radiation dose, specifically 312 
with doses >15 Gy14. Another study showed increased risks specifically with doses >5 Gy to 313 
the uterus and in a smaller sub-cohort treated prior to menarche, an even lower threshold 314 
of 2.5 Gy12. One study showed that chemotherapy was associated with an increased risk of 315 
premature birth (low level evidence)11. However, this effect was not found in a small 316 
Japanese study35 or in a large Australian population-based study9. One study did not observe 317 
a significant effect of alkylating agent dose on  risk of premature birth (very low level 318 
evidence)12. 319 
 320 
Low birth weight 321 
There is moderate level evidence for an increased risk of low birth weight (below 2500 322 
grams) delivery in CAYA cancer survivors as compared to controls9-13, 27, 35 and high level 323 
evidence for this outcome after  radiotherapy to volumes exposing the uterus9, 11, 13, 28, 30, 34, 324 
35. A dose response relationship was observed in survivors of Wilms tumor31 and risk of an 325 
effect of radiotherapy was  observed after >2.5 Gy12 to the uterus and >25 Gy30 326 
abdominopelvic radiotherapy (moderate level evidence)12, 30. While three studies did not 327 
identify chemotherapy as a risk factor for  low birth weight9, 30, 35, the association was 328 
suggested in one report11(very low level evidence). There also seems to be no effect of 329 
alkylating agent dose (very low level evidence) on the risk of giving birth to a child with a low 330 
birth weight12. 331 
 332 
Small for gestational age  333 
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There is low level evidence for no increased risk of small for gestational age (SGA; <10th 334 
percentile birth weight for gestational age) delivery among CAYA cancer survivors in general 335 
as compared to controls11, 12, 35. Although radiotherapy versus no radiotherapy was not 336 
found to be significantly associated with this outcome in four studies13, 28, 30, 35, two studies 337 
showed that patients treated with specific doses of abdominopelvic radiotherapy (>5 Gy and 338 
>25 Gy, respectively) did have an increased risk (low level evidence)12, 30. 339 
 340 
Evidence for mode of delivery 341 
Vaginal delivery 342 
There is high level evidence indicating that rates of spontaneous vaginal births are lower in 343 
CAYA cancer survivors compared to controls8, 10. There was no significant difference 344 
between survivors and controls (moderate level evidence)8, 10, 13, and no significant effect of 345 
radiotherapy (very low level evidence)13 on occurrence of assisted vaginal delivery.  346 
 347 
Cesarean delivery 348 
There is low level evidence for higher rates of “any cesarean section” (data from reports that 349 
did not distinguish between elective (primary) and emergency (secondary/urgent) cesarean 350 
sections) among CAYA cancer survivors as compared to controls9-11, 35, including reports 351 
evaluating prevalence  after radiotherapy and chemotherapy (low level evidence)9, 35.  352 
High level evidence was identified for an increased rate of an elective cesarean delivery8, 10, 353 
11, 34, especially after abdominopelvic radiotherapy (moderate level evidence)34. No 354 
significantly increased rate was observed for the occurrence of emergency cesarean delivery 355 
(moderate level evidence)8, 10, 13, 34. Radiotherapy nor age at diagnosis significantly affected 356 
the rate of emergency cesarean section (high level evidence)8, 13, 34  357 
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 358 
Evidence for risks related to delivery 359 
Postpartum hemorrhage  360 
There is low level evidence for an increased risk of postpartum hemorrhage in CAYA cancer 361 
survivors as compared to controls. An increased risk was observed in one report8 but not in 362 
four others9, 10, 13, 34. There is low level evidence for a statistically significant effect of 363 
abdominal radiotherapy for this outcome based on one small study suggesting an increased 364 
risk 13, while  another larger study did not find an increased risk34.  365 
 366 
Evidence for problems of the neonate 367 
Congenital anomalies 368 
There is high level evidence that there is no increased risk of congenital anomalies among 369 
neonates of CAYA cancer survivors as compared to controls. Nine studies, with large 370 
heterogeneity in outcome definitions, have reported on the prevalence of congenital 371 
anomalies and none showed an increased risk9, 11, 13, 32, 36-40. There is also high level evidence 372 
that there is no significant effect of radiotherapy delivered as part of CAYA  cancer therapy 373 
on the risk of congenital anomalies13, 30, 36, 38, 39, 41, 42. 374 
 375 
Evidence for additional obstetric outcomes 376 
The evidence levels on the risk of retained placenta/manual removal of the placenta, 377 
placental pathologies, fetal growth restriction, uterine scar from previous surgery and 378 
perineal laceration/rupture were low to very low or revealed no increased risk for these 379 
outcomes. Concerning the neonate, the evidence levels on the risk of resuscitation and 380 
admission to a special care unit were very low. Additional outcomes evaluated in a very 381 
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limited number of papers are reported in Appendix 6, also demonstrating only low to very 382 
low levels of evidence.  383 
 384 
Translating evidence into recommendations 385 
Final recommendations,  formulated based on at least moderate or high levels of evidence 386 
for the risk of obstetric outcomes and its determinants (Table 1) are summarized in Table 2. 387 
There was moderate level evidence for an increased risk of miscarriage after radiotherapy to 388 
volumes exposing the uterus, and high level evidence for an increased risk of premature 389 
birth (<37 weeks of gestation) and low birth weight (<2500 grams) after radiotherapy to 390 
volumes exposing the uterus. In addition, CAYA cancer survivors had higher rates of elective 391 
cesarean section (high level evidence). There was high level evidence that there is no 392 
increased risk of congenital anomalies in the offspring of CAYA cancer survivors. Lower levels 393 
of evidence were included for the identification of gaps in knowledge and future research 394 
directions (Panel). Radiotherapy was of specific interest if and when a dose-response 395 
relationship was identified. Although low level evidence suggests a dose-response 396 
relationship of radiotherapy to volumes exposing the uterus with the risk of miscarrriage29, 397 
30, insufficient evidence is available to identify a safe threshold dose.   398 
For every adverse outcome, the balance between benefits and harms of preconception 399 
counseling and surveillance, resource use, acceptability to stakeholders and feasibility or 400 
barriers for implementation was considered. The panel agreed that, in general,  all female 401 
CAYA cancer survivors of reproductive age should be informed by healthcare providers about 402 
their potential risk for adverse obstetric outcomes based on cancer treatment exposures 403 
(strong recommendation).  404 
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For example, female CAYA cancer survivors treated with radiotherapy to volumes exposing 405 
the uterus and their health care providers should be aware of the risk of adverse obstetric 406 
outcomes including miscarriage (moderate quality evidence), premature birth (high quality 407 
evidence) and low birth weight (high quality evidence). In addition, high risk obstetric 408 
surveillance is recommended for this patient group (strong recommendations). The panel 409 
agreed that the benefits of preconception counseling and obstetric surveillance for these 410 
outcomes (i.e., early detection of fetal growth restriction or threatened premature delivery 411 
requiring intervention to ensure optimal neonatal outcome) clearly outweigh the potential 412 
harms (e.g., stress, anxiety and potential higher health care costs).  413 
Regarding the increased likelihood of elective cesarean section, the panel agreed that no 414 
recommendations could be drawn as this risk may be attributable to myriad factors 415 
including the survivor’s or the healthcare provider’s concern.  416 
The absence of an increased risk of congenital anomalies (high quality evidence) is of great 417 
importance to survivors and the panel agreed that female CAYA cancer survivors and their 418 
health care providers should be aware of this (strong recommendation).  419 
Based on previous recommendations from the IGHG for cardiomyopathy surveillance for 420 
CAYA cancer survivors, cardiomyopathy surveillance is reasonable prior to pregnancy or in 421 
the first trimester for all female survivors treated with anthracyclines and/or chest radiation 422 
(moderate recommendation)43. No recommendations have been formulated for the 423 
frequency of ongoing cardiomyopathy surveillance in pregnant survivors who have normal 424 
left ventricular systolic function immediately prior to or during the first trimester of 425 
pregnancy. However, the IGHG panel recommended that health care providers remain alert 426 
for cardiomyopathy in survivors treated with anthracyclines and/or chest-directed radiation 427 
who present with commonly reported symptoms such as shortness of breath, fatigue, and 428 
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ankle swelling43. The panel additionally emphasized that CAYA cancer survivors with 429 
compromised left ventricular systolic function (<30%) before pregnancy are more likely to 430 
have further reduction in cardiac function during pregnancy or post-partum, irrespective of 431 
lifetime anthracycline dose43.  432 
 433 
COMMENT  434 
This paper presents the IGHG recommendations for counseling and surveillance of female 435 
CAYA cancer survivors before and during pregnancy. Evidence-based recommendations for 436 
survivor risk groups were formulated to facilitate consistent long-term follow-up care, 437 
optimize the quality of care and minimize burden of disease and unnecessary surveillance. 438 
As a result of this effort,  the guideline panel also stressed the need for future research in 439 
larger cohorts to advance understanding about the radiotherapy dose response relationship 440 
to adverse obstetric outcomes. 441 
Critical evaluation of the published literature aided by the GRADE methodology yielded 442 
moderate level evidence that CAYA cancer survivors are at increased risk of miscarriage after 443 
radiotherapy9, 23, 24, 26, 28, 29, 31. When reported, the definition of a miscarriage was 444 
heterogeneous (usually pregnancies ending before gestational week 20 or, in the BCCSS, 445 
before 24 weeks) and the panel acknowledged the potential for reporting bias in both self-446 
reported and registry-based data. However, increased risks were observed in three large 447 
cohorts, from the North American Childhood Cancer Survivor Study (CCSS) (self-reported 448 
miscarriage, not further specified14), Australia (registered threatened miscarriage after 20 449 
weeks of gestation9) and Denmark (registered spontaneous abortion, not further 450 
specified29). Although low level evidence suggests a dose-response relationship with 451 
radiotherapy to volumes exposing the uterus29, 30, there is insufficient evidence to identify a 452 
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safe threshold dose. Even though there is no specific action to reduce this risk, the panel 453 
agreed survivors need to be counseled of their potential increased risk of miscarriage.  454 
Lack of definition of termination of pregnancy14, 29, 32 and broad and overlapping definitions 455 
of stillbirth (e.g. the fetus not surviving after 20 weeks of gestation9, after 28 weeks29, or 456 
combined with neonatal deaths within the first 28 days of life33), and potential reporting bias 457 
resulted in a low body of evidence on which to base recommendations (Panel).  458 
Interestingly, a recent study in survivors aged 39 years or less at cancer diagnosis with robust 459 
outcome reporting showed a significantly reduced risk of termination of pregnancy44, 460 
stressing the need for further research to define more accurately the prevalence of this 461 
outcome.  462 
We identified high level evidence for the increased risks of premature birth and low birth 463 
weight after radiotherapy to volumes exposing the uterus9-14, 27, 28, 30, 31, 34, 35. The evidence 464 
for dose-response relationships between radiotherapy and miscarriage, premature birth and 465 
low birth weight is compelling, but clear evidence to determine a safe threshold dose is 466 
lacking. Different approaches have been used to assess radiotherapy dose, giving rise to bias 467 
when comparing these studies12, 27, 29, 30, 45. In modern clinical practice, approximation of 468 
organ-specific radiation exposure parameters that are much closer to the individual true 469 
dose distribution during treatment is feasible, and expected to facilitate a more accurate 470 
assessment of the relationship of radiation dose and obstetric risks, in future studies.   471 
Radiotherapy to volumes exposing the ovaries, that is, radiotherapy targeting the lower 472 
body and thereby exposing the ovaries to substantial amounts of ionizing radiation, is 473 
associated with premature ovarian insufficiency46-49  but does not lead to increased risks of 474 
stillbirth or congenital anomalies as compared to the general population. Mechanisms 475 
leading to increased rates of miscarriage, premature delivery and low birth weight have not 476 
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been completely elucidated, but several hypotheses have been proposed. Radiotherapy to 477 
volumes exposing the uterus can damage the uterine vasculature and muscular 478 
development50, and potentially impair endometrial function due to impaired blood supply. 479 
This may result in poor implantation of the embryo and poor placental growth which could 480 
contribute to subsequent early miscarriage. The increased risks of premature birth and low 481 
birth weight may result from uterine vasculature injury leading to impaired utero-placental 482 
blood flow, insufficient placental development and hence fetal growth restriction, or may 483 
result from a reduced uterine elasticity and volume50, 51. Additionally, hormonal deficiency as 484 
a consequence of ovarian failure may lead to smaller uterine volumes51.  485 
Cancer survivors should be counseled about obstetric risks when developmentally and 486 
clinically appropriate. Multimorbidity is often the norm in CAYA cancer survivors, 487 
emphasizing the need to understand specific treatment-related risks and how collectively 488 
these conditions may impact the course of pregnancy. Communication among obstetric and 489 
oncology providers and survivors is key in these complicated cases. Preconception 490 
consultation and obstetric surveillance may lead to referral to a specialized obstetric team 491 
rather than a general obstetric or midwifery team and ensure selection of a hospital for the 492 
place of birth rather than a birth center or home. Further clinical management, such as 493 
antenatal monitoring for heightened risk of low birth weight or cardiac monitoring, should 494 
adhere to established obstetric care guidelines.  495 
No recommendations were formulated based on the high level of evidence concerning the 496 
increased likelihood of an elective cesarean section. The increased obstetric risks of cancer 497 
survivors may influence the varied clinical, cultural and personal factors for patients and 498 
providers that contribute to  decision making about elective cesarean sections. Reassuringly, 499 
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the  likelihood of an emergency cesarean section was not increased among women treated 500 
with  radiotherapy. 501 
A large and consistent body of evidence indicates that neonates of CAYA cancer survivors 502 
treated with and without radiotherapy are not at increased risk of congenital anomalies13, 30, 503 
36, 38, 39, 41, 42. As this is often a major concern in CAYA cancer survivors, the panel 504 
recommends reassurance of CAYA cancer survivors that there is no indication of such an 505 
increased risk.  506 
The recommendations presented here have benefited from the systematic appraisal of bias 507 
and transparent implementation of GRADE in assessing the available evidence. Their 508 
relevance is further strengthened by the careful considerations that the multidisciplinary 509 
and international panel made by extrapolating evidence to recommendations. Some 510 
limitations include variability of definitions of outcomes and availability of specific details 511 
regarding radiotherapy (dose and site) and chemotherapy (agents and dose) across studies, 512 
potential study biases without indication of response rates, and the scarcity of studies with 513 
multivariable analyses to address confounding clinical issues. In addition, the body of 514 
evidence often indicated no increased risk, but few power calculations were presented in 515 
the papers to distinguish between absence of evidence and evidence of absence of an 516 
association. We note that we have not addressed thyroid dysfunction in CAYA cancer 517 
survivors, an important topic as latent hypothyroidism can impact fetal brain development15, 518 
16. Recommendations on surveillance will be formulated in an upcoming IGHG guideline on 519 
surveillance of thyroid dysfunction. A periodic update of the obstetric recommendations is 520 
planned, and the IGHG thyroid dysfunction surveillance recommendations will then also be 521 
included.  522 
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The identification of key gaps in knowledge is an important result of the harmonization 523 
process (Panel). These evidence gaps should be addressed in strong methodical and 524 
comprehensive studies from sufficiently large cohorts, or preferably international 525 
multicenter collaborative projects to increase generalizability of the results.  526 
 527 
CONCLUSION 528 
This IGHG analysis identified specific adverse obstetric related outcomes that are increased 529 
in CAYA cancer survivors to characterize the population that will benefit specifically from an 530 
individualized preconception consultation and pregnancy surveillance. Key findings are that 531 
there are increased risks of premature delivery and low birth weight associated with 532 
radiotherapy targeting the lower body and thereby exposing the uterus, which warrant high-533 
risk pregnancy surveillance, and that survivors should be reassured there is no increased risk 534 
of congenital abnormality. 535 
 536 
  537 
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Table 1. Overall conclusions of evidence for obstetric risks in female childhood and adolescent cancer 687 
survivors (key outcomes) 688 
Who needs preconception counseling? Who needs high-risk pregnancy surveillance? 
Risk of miscarriage in female cancer survivors diagnosed before age 25 years  Level of evidence* 
No increased risk in CAYA cancer survivors vs controls. ⊕⊕⊕⊖ MODERATE
9, 24, 
25, 27, 29, 32 
Increased risk after (abdominopelvic) radiotherapy vs. no radiotherapy. ⊕⊕⊕⊖ MODERATE
9, 14, 
23-29
 
Increased risk with increasing doses of abdominopelvic and pituitary radiotherapy vs. 
no radiotherapy. 
⊕⊕⊖⊖ LOW
29, 30 
No significant effect of chemotherapy vs. no chemotherapy. ⊕⊕⊕⊖ MODERATE
9, 14, 
25, 26, 30
 
Increased risk after chemotherapy and radiotherapy (no specific field) vs. no 
chemotherapy and radiotherapy. 
 
⊕⊕⊖⊖ LOW
9, 14, 24, 25, 30
 
No significant effect of age at diagnosis. ⊕⊕⊖⊖ LOW
9
 
Risk of terminations in female cancer survivors diagnosed before age 25 years Level of evidence 
No increased risk in CAYA cancer survivors vs controls. ⊕⊖⊖⊖ VERY LOW
29, 32
 
Increased risk after radiotherapy vs. no radiotherapy. ⊕⊕⊖⊖ LOW
14, 26
 
Increased risk after chemotherapy vs. no chemotherapy. ⊕⊖⊖⊖ VERY LOW
14, 26
 
Increased risk after chemotherapy and/or radiotherapy (to any field or gonadal) vs. no 
chemotherapy and radiotherapy. 
⊕⊕⊖⊖ LOW
14, 23
 
Risk of stillbirth in female cancer survivors diagnosed before age 25 years Level of evidence 
No increased risk in CAYA cancer survivors vs controls. ⊕⊕⊕⊖ MODERATE
9, 29
 
No significant effect of radiotherapy vs. no radiotherapy. ⊕⊕⊖⊖ LOW
9, 14, 26, 30, 41
 
Increased risk after high-dose ovarian-abdominal radiotherapy vs. no radiotherapy.
 
⊕⊕⊖⊖ LOW
30, 33, 41 
Increased risk after abdominopelvic radiotherapy (>1.00 Gy) given before menarche 
vs. no radiotherapy, but no significant effect when given after menarche 
⊕⊕⊖⊖ LOW
33
 
No significant effect of chemotherapy vs. no chemotherapy.  ⊕⊕⊖⊖ LOW
9, 14, 26, 30
 
No significant effect of alkylating agent dose. ⊕⊕⊖⊖ LOW
33
 
No significant effect of alkylating agents in combination with abdominal-pelvic 
radiation vs. no alkylating agents and abdominal-pelvic radiation. 
⊕⊕⊖⊖ LOW
14, 23, 30
 
Risk of gestational hypertension in female cancer survivors diagnosed before age 25 
years 
Level of evidence 
No increased risk in CAYA cancer survivors vs controls. ⊕⊖⊖⊖ VERY LOW
13, 35
 
Increased risk after abdominopelvic radiotherapy vs. no radiotherapy. ⊕⊖⊖⊖ VERY LOW
13, 34, 
35
 
Increased risk with increasing doses of flank radiotherapy in CAYA Wilms tumor 
survivors. 
⊕⊖⊖⊖ VERY LOW
45
 
No significant effect of chemotherapy vs. no chemotherapy. ⊕⊖⊖⊖ VERY LOW
35
 
No significant effect of age at diagnosis. ⊕⊕⊖⊖ LOW
34
 
Risk of pre-eclampsia in female cancer survivors diagnosed before age 25 years Level of evidence 
Increased risk in CAYA cancer survivors vs controls. ⊕⊕⊖⊖ LOW
9, 11, 13
 
No significant effect of abdominopelvic radiotherapy vs. no radiotherapy. ⊕⊖⊖⊖ VERY LOW
13
 
Risk of maternal anemia in female cancer survivors diagnosed before age 25 years Level of evidence 
No increased risk in CAYA cancer survivors vs controls. ⊕⊕⊕⊖ MODERATE
9, 11
 
Increased risk after (abdominopelvic) radiotherapy vs. no radiotherapy. ⊕⊕⊖⊖ LOW
11, 34
 
Increased risk after chemotherapy vs. no chemotherapy. ⊕⊕⊖⊖ LOW
11
 
No significant effect of radiotherapy and chemotherapy vs. controls. ⊕⊕⊖⊖ LOW
11
 
No significant effect of age at diagnosis.  ⊕⊕⊕⊖ MODERATE
11, 34
 
Risk of gestational diabetes in female cancer survivors diagnosed before age 25 
years 
Level of evidence 
Increased risk in CAYA cancer survivors vs controls. ⊕⊕⊖⊖ LOW
9, 11, 35
 
Increased risk after (abdominopelvic) radiotherapy vs. no radiotherapy. ⊕⊕⊖⊖ LOW
9, 11, 34, 35
 
28 
 
No significant effect of chemotherapy vs. no chemotherapy. ⊕⊕⊕⊖ MODERATE
9, 11, 
35
 
Increased risk after chemotherapy in combination with radiotherapy vs. controls. ⊕⊖⊖⊖ VERY LOW
9, 11
 
No significant effect of age at diagnosis. ⊕⊕⊕⊕ HIGH
9, 11, 34
 
Risk of malposition in female cancer survivors diagnosed before age 25 years Level of evidence 
No increased risk in CAYA cancer survivors vs. controls. ⊕⊖⊖⊖ VERY LOW
10
 
No significant effect of radiotherapy vs. no radiotherapy. ⊕⊕⊖⊖ LOW
34
 
Increased risk with increasing doses flank radiation. ⊕⊖⊖⊖ VERY LOW
45
 
No significant effect of age at diagnosis. ⊕⊕⊕⊕ HIGH
10, 34
 
Risk of postpartum hemorrhage in female cancer survivors diagnosed before age 25 
years 
Level of evidence 
Increased risk in CAYA cancer survivors vs controls. ⊕⊕⊖⊖ LOW
8-10, 13, 34
 
Increased risk after abdominopelvic radiotherapy vs. no radiotherapy. ⊕⊖⊖⊖ VERY LOW
13, 34
 
No significant effect of age at diagnosis. ⊕⊕⊖⊖ LOW
34
 
Risk of premature birth in female cancer survivors diagnosed before age 25 years Level of evidence 
Increased risk in CAYA cancer survivors vs. controls. ⊕⊕⊕⊖ MODERATE
9-13, 
27, 35
 
Increased risk after (abdominopelvic) radiotherapy vs. no radiotherapy. ⊕⊕⊕⊕ HIGH
9, 11, 13, 28, 34, 
35
 
Increased risk with increasing doses of ovarian-abdominal radiotherapy (>5/15 Gy). ⊕⊕⊖⊖ LOW
12, 45
 
Increased risk after chemotherapy vs. no chemotherapy.  ⊕⊕⊖⊖ LOW
9, 11, 35
 
No significant effect of alkylating agent dose. ⊕⊕⊖⊖ LOW
12
 
Increased risk after radiotherapy and chemotherapy vs. no radiotherapy and 
chemotherapy. 
⊕⊕⊕⊖ MODERATE
9, 11
 
Increased risk in survivors aged >5 yrs at cancer diagnosis vs. controls, but no 
significant effect in survivors aged <5 yrs at cancer diagnosis 
⊕⊕⊖⊖ LOW
9, 11, 34
 
Risk of low birth weight in female cancer survivors diagnosed before age 25 years Level of evidence 
Increased risk in CAYA cancer survivors vs controls. ⊕⊕⊕⊖ MODERATE
9-13, 
27, 35
 
Increased risk after (abdominopelvic) radiotherapy vs. no radiotherapy. ⊕⊕⊕⊕ HIGH
9, 11, 13, 28, 30, 
34, 35
 
Increased risk after increasing doses of abdominopelvic radiotherapy (>2.5/25 Gy)  ⊕⊕⊕⊖ MODERATE
12, 27, 
30, 45
 
Increased risk after chemotherapy vs. no chemotherapy.  ⊕⊖⊖⊖ VERY LOW
9, 11, 30, 
35
 
No significant effect alkylating agent dose. ⊕⊖⊖⊖ VERY LOW
12
 
Increased risk after radiotherapy and chemotherapy vs. no radiotherapy and 
chemotherapy. 
⊕⊖⊖⊖ VERY LOW
9, 11, 30
 
Increased risk in survivors aged ≥20 yrs at cancer diagnosis vs. controls, but no 
significant effect in survivors aged <20 yrs at cancer diagnosis 
⊕⊖⊖⊖ VERY LOW
9, 11, 34
 
Risk of delivery of a child small for gestational age in female cancer survivors 
diagnosed before age 25 years 
Level of evidence 
No increased risk in CAYA cancer survivors vs. controls. ⊕⊕⊖⊖ LOW
11, 12, 35
 
No significant effect of (abdominopelvic) radiotherapy vs. no radiotherapy. ⊕⊕⊖⊖ LOW
13, 28, 30, 35
 
Increased risk after increasing doses of abdominopelvic radiotherapy. ⊕⊕⊖⊖ LOW
12, 30
 
No significant effect of chemotherapy vs. no chemotherapy. ⊕⊖⊖⊖ VERY LOW
35
 
No significant effect of alkylating agent dose. ⊕⊕⊖⊖ LOW
12
 
No significant effect of radiotherapy and chemotherapy vs. surgery only. ⊕⊖⊖⊖ VERY LOW
30
 
Risk of intrauterine growth restriction in female cancer survivors diagnosed before 
age 25 years 
Level of evidence 
No increased risk in CAYA cancer survivors vs. controls. ⊕⊖⊖⊖ VERY LOW
9
 
Likelihood of vaginal delivery in female cancer survivors diagnosed before age 25 
years 
Level of evidence 
Decreased likelihood of vaginal birth in in CAYA cancer survivors vs. controls. ⊕⊕⊕⊕ HIGH
8, 10
 
Likelihood of assisted vaginal delivery in female cancer survivors diagnosed before Level of evidence 
29 
 
age 25 years 
No increased likelihood of in CAYA cancer survivors vs. controls. ⊕⊕⊕⊖ MODERATE
8, 10, 
13
 
No significant effect of radiotherapy vs. no radiotherapy. ⊕⊖⊖⊖ VERY LOW
13
 
No significant effect of age at diagnosis. ⊕⊕⊖⊖ LOW
10
 
Risk of any cesarean section in female cancer survivors diagnosed before age 25 
years 
Level of evidence 
Increased likelihood of any cesarean section in in CAYA cancer survivors vs controls. ⊕⊕⊖⊖ LOW
9-11, 35
 
Increased likelihood after radiotherapy vs. no radiotherapy. ⊕⊕⊖⊖ LOW
9, 35
 
Increased likelihood after chemotherapy vs. no chemotherapy, ⊕⊕⊖⊖ LOW
9, 35
 
Significant effect of age at diagnosis (increased effect if 0-14 yrs at diagnosis) ⊕⊖⊖⊖ VERY LOW
9, 10
 
Likelihood of an elective/primary cesarean section in female cancer survivors 
diagnosed before age 25 years 
Level of evidence 
Increased likelihood in CAYA cancer survivors vs controls. ⊕⊕⊕⊕ HIGH
8, 10, 11, 34
 
Increased likelihood after radiotherapy vs. no radiotherapy, specifically after 
abdominal radiotherapy in Wilms survivors. 
⊕⊕⊕⊖ MODERATE
34
 
No significant effect of age at diagnosis. ⊕⊕⊕⊕ HIGH
34
 
Likelihood of an emergency/secondary/urgent cesarean section in female cancer 
survivors diagnosed before age 25 years 
Level of evidence 
No increased likelihood in CAYA cancer survivors vs controls. ⊕⊕⊕⊖ MODERATE
8, 10, 
13, 34
 
No significant effect of radiotherapy vs. no radiotherapy. ⊕⊕⊕⊕ HIGH
13, 34
 
No significant effect of age at diagnosis. ⊕⊕⊕⊖ MODERATE
8, 34
 
Risk of congenital anomalies/abnormalities in female cancer survivors diagnosed 
before age 25 years 
Level of evidence 
No increased risk in CAYA cancer survivors vs controls. ⊕⊕⊕⊕ HIGH
9, 11, 13, 32, 36-
40
 
No significant effect of (ovarian-abdominal) radiotherapy vs. no radiotherapy. ⊕⊕⊕⊕ HIGH
13, 30, 36, 38, 
39, 41, 42
 
No significant effect of radiotherapy dose. ⊕⊕⊕⊖ MODERATE
30, 36, 
41, 42, 45
 
No significant effect of alkylating agents vs. no alkylating agents.  ⊕⊕⊕⊖ MODERATE
30, 38, 
39, 41, 42, 52
 
No significant effect of alkylating agent dose.  ⊕⊖⊖⊖ VERY LOW
42
 
No significant effect of alkylating agents in combination with abdominal-pelvic 
radiation vs. no alkylating agents and abdominal-pelvic radiation.  
⊕⊕⊕⊖ MODERATE 
23, 30, 
41
 
No significant effect of age at diagnosis. ⊕⊖⊖⊖ VERY LOW
39
 
Rate of supervision of high-risk pregnancy in female cancer survivors diagnosed 
before age 25 years 
Level of evidence 
No increased rates in CAYA cancer survivors vs controls. ⊕⊕⊖⊖ LOW
34
 
No significant effect of radiotherapy vs. no radiotherapy. ⊕⊕⊖⊖ LOW
34
 
Risk of retained placenta/manual removal of the placenta in female cancer 
survivors diagnosed before age 25 years 
Level of evidence 
No increased risk in CAYA cancer survivors vs. controls. ⊕⊕⊖⊖ LOW
9, 13
 
Risk of placental pathologies in female cancer survivors diagnosed before age 25 
years 
Level of evidence 
No increased risk in CAYA cancer survivors vs. controls. ⊕⊖⊖⊖ VERY LOW
10
 
Risk of resuscitation of the neonate born to female cancer survivors diagnosed 
before age 25 years 
Level of evidence 
Increased risk in CAYA cancer survivors vs. controls. ⊕⊖⊖⊖ VERY LOW
9
 
Likelihood of admission to a special care unit in neonates born to female cancer 
survivors diagnosed before age 25 years 
Level of evidence 
Increased likelihood in CAYA cancer survivors vs. controls. ⊕⊖⊖⊖ VERY LOW
9
 
*Citations refer to papers on which the GRADE level of evidence was based on, and do not 689 
necessarily support the overall conclusion. 690 
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Table 2. Harmonized recommendations for counseling and surveillance in pregnancy  692 
General recommendation 
Health care providers should discuss the risk of adverse obstetric outcomes based on the specific 
cancer treatment exposures with all female CAYA cancer survivors of reproductive age. 
Who needs preconception counseling? 
Female CAYA cancer survivors and their health care providers should be aware that there is no 
evidence to support that survivors have an increased risk of giving birth to a child with congenital 
anomalies (high quality evidence). 
Female CAYA cancer survivors treated with radiotherapy to volumes exposing the uterus and their 
health care providers should be aware of the risk of adverse obstetric outcomes including 
miscarriage (moderate quality evidence), premature birth (high quality evidence) and low birth 
weight (high quality evidence). 
Who needs specific obstetric surveillance during pregnancy? 
High risk obstetric surveillance is recommended for CAYA cancer survivors treated with 
radiotherapy to volumes exposing the uterus due to the risk of premature birth and low birth 
weight (high quality evidence). 
 693 
Who needs specific cardiac surveillance during pregnancy? Based on IGHG cardiomyopathy 
guideline
43 
Cardiomyopathy surveillance is reasonable prior to pregnancy or in the first trimester for all female 
survivors treated with anthracyclines and/or chest radiation (moderate level recommendation, 
moderate quality evidence)43. 
No recommendations can be formulated for the frequency of ongoing surveillance in pregnant 
survivors who have normal left ventricular systolic function immediately prior to or during the first 
trimester of pregnancy (moderate level recommendation, low quality evidence)43. 
 694 
  695 
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 696 
Panel: Gaps in knowledge and future directions for research of obstetric outcomes in CAYA 
cancer survivors  
• Risks of medical and elective termination of pregnancy following CAYCA cancer, 
including standardized definitions of this outcome and its confounders 
• Risks of gestational diabetes, gestational hypertension and pre-eclampsia, giving birth 
to babies small for gestational age, very premature delivery (<32 weeks of gestation) or 
postpartum hemorrhage 
• Effect of radiotherapy and dose-response relationships to specific volumes (e.g., 
uterus) on obstetric outcomes 
• Influence of relatively low doses of radiotherapy (including 10-15 Gy) that reach the 
uterus on obstetric outcomes 
• Effect of age at cancer diagnosis and pubertal stage at treatment on all obstetric risks 
• The contribution of environmental factors known to affect obstetric outcomes (e.g., 
BMI, smoking)  
• The contribution of obstetric risk associated with artificial reproductive technology 
(ART), especially as fertility rates after ART (including donor oocytes) increase 
• Development of a risk prediction algorithm for outcomes including miscarriage, 
premature delivery and low birth weight, taking into account, e.g., age at cancer 
diagnosis, cancer treatment, maternal age, smoking, parity and ART 
• Methods to optimize timely provision of information about obstetric risk to CAYA 
cancer survivors in a variety of health care systems and health literacy settings 
• The effect of high risk surveillance on clinical relevant outcomes for survivors at risk 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Flowchart of selected studies. Articles could be included for multiple working groups (WG). 
Four working groups respectively evaluated the following topics: 1) adverse fetal outcomes in 
pregnancy (such as miscarriage); 2) adverse maternal outcomes in pregnancy; 3) delivery outcomes; 
and 4) congenital anomalies of the neonate. 
 
Records excluded based on title and abstract 
N = 5,166 
Articles identified for guideline 
N = 28 
Records identified through PubMed search for 
pregnancy and delivery related risks 
(January 1990-December 2018) 
N = 2,772 
Articles included for 
WG 1 
N = 13 
 
Full text assessment 
N = 98 
Records identified through PubMed search for 
congenital anomalies 
 (January 1990-December 2018) 
N = 2,492 
Records excluded based on full text 
(main reasons: review, no CAYA cancer 
survivors) 
N = 70 
Articles included for 
WG 2 
N = 8 
Articles included for 
WG 3 
N = 12 
Articles included for 
WG 4 
N = 15 
